Morgan Stanley Upgrades Merck & Co to Overweight, Raises Price Target to $179

Benzinga Newsdesk www.benzinga.com Positive 86.3%

Neg 0% Neu 0% Pos 86.3%

Morgan Stanley analyst Terence Flynn upgrades Merck & Co (NYSE:MRK) from Equal-Weight to Overweight and raises the price target from $116 to $179.